{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:57:10Z","timestamp":1785164230563,"version":"3.55.0"},"reference-count":6,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intervirology"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point-of-care rapid testing kits. However, some rapid test kits have low specificity and can generate false positives. Hence, we aimed to investigate the potential serological cross-reactivity between SARS-CoV-2 and DENV-IgG antibodies using advanced assays including chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) test. A total of 90 DENV-IgG-ELISA-positive and 90 DENV-IgG-ELISA-negative prepandemic sera were tested for anti-SARS-CoV-2-IgG using the automated CL-900i CLIA assay. Furthermore, a total of 91 SARS-CoV-2-IgG-CLIA-positive and 91 SARS-CoV-2-IgG-CLIA-negative postpandemic sera were tested for anti-DENV-IgG using the NovaLisa ELISA kit. The DENV-IgG-positive sera resulted in five positives and 85 negatives for SARS-CoV-2-IgG. Similarly, the DENV-IgG-negative sera also resulted in 5 positives and 85 negatives for SARS-CoV-2-IgG. No statistically significant difference in specificity between the DENV-IgG-positive and DENV-IgG-negative sera was found (&lt;i&gt;p&lt;\/i&gt; value = 1.00). The SARS-CoV-2-IgG-positive sera displayed 43 positives, 47 negatives, and 1 equivocal for DENV-IgG, whereas the SARS-CoV-2-IgG-negative sera resulted in 50 positives, 40 negatives, and 1 equivocal for DENV-IgG. No statistically significant difference in the proportion that is DENV-IgG positive between the SARS-CoV-2-IgG-positive and SARS-CoV-2-IgG-negative sera (&lt;i&gt;p&lt;\/i&gt; value = 0.58). In conclusion, there is a low risk of serological cross-reactivity between the DENV and SARS-CoV-2-IgG antibodies when using advanced detection assays.<\/jats:p>","DOI":"10.1159\/000522479","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T17:00:44Z","timestamp":1644339644000},"page":"224-229","source":"Crossref","is-referenced-by-count":9,"title":["Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays"],"prefix":"10.1159","volume":"65","author":[{"given":"Farah M.","family":"Shurrab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0487-3365","authenticated-orcid":false,"given":"Duaa W.","family":"Al-Sadeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Humaira","family":"Amanullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas S.","family":"Al-Absi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Qotba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-2788","authenticated-orcid":false,"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-0506","authenticated-orcid":false,"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheyath K.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617089"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9363-2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760200225"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24916"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.12.037"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.09.005"}],"container-title":["Intervirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/522479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/522479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:51:12Z","timestamp":1745409072000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000522479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":6,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,21]]}},"URL":"https:\/\/doi.org\/10.1159\/000522479","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.19.21255725","asserted-by":"object"}]},"ISSN":["0300-5526","1423-0100"],"issn-type":[{"value":"0300-5526","type":"print"},{"value":"1423-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}